1 / 14

Bruce Minsky

Do all patients with T2-3 mid-high rectal adenocarcinomas require RT as part of their neoadjuvant therapy? - Yes -. Bruce Minsky. Colon vs. Rectal Cancer. Colon: Time to Recurrence. Sargent et al JCO 2007. CAO/ARO/AIO 94. Roedel et al JCO 2012. Preoperative Staging.

evita
Download Presentation

Bruce Minsky

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Do all patients with T2-3 mid-high rectal adenocarcinomas require RT as part of their neoadjuvant therapy? - Yes - Bruce Minsky

  2. Colon vs. Rectal Cancer

  3. Colon: Time to Recurrence Sargent et al JCO 2007

  4. CAO/ARO/AIO 94 Roedel et al JCO 2012

  5. Preoperative Staging TRUS or MRI: T stage: 90% N stage: 60-70% MRI + contrast*: T stage: 90% N stage: 70-80% (↑ appx 10%) *Gadofosveset (Lambregts, Ann Surg 2011) *Iron oxide (Will et al, Lancet Oncol 2006)

  6. Risk of LN+ by Distance Guillem pooled analysis · 188 Pts with cT3N0 s/p preop CMT · 6 international centers Cm from AV#% ypN+ 0-5 103 23 5-12 85 20 High tumors have equivalent risk of LN+ Guillem et al JCO 2008

  7. cT3N0 @ 10 cm: CMT vs. LAR PREOP CMT - improved local control - less toxicity - but over treat 20% (pT1-2N0) SURGERY - avoid RT - but if N+ (22% s/p preop CMT*) then need postop CMT - decreased local control - higher toxicity - poor function Guillem et al JCO 2008

  8. Distance from the AV Caveats: · All are subset analysis · Include cT1-3 tumors · Variable methods to measure distance · 5 Gy x 5 · Dutch: flexible scope, < 15 cm, TME · German: rigid scope, < 16 cm, TME · SRCT: no details, variable surgery

  9. Distance from the AV Surgery Preop RT Cm% 5-Yr LF% 5-Yr LFp Dutch High 10.1-15 6 4 - Mid 5.1-10 14 4 <0.001 Low < 5 12 11 - SRCT High > 11 12 8 - Mid 6-10 26 9 <0.001 Low < 5 27 10 0.003

  10. Distance from the AV German Pre-op Location#%10-Yr LF < 6 cm 166 11 6- <12 cm 166 5 12-16 cm 37 10

  11. Preop CMT – Selective RT ∙ 32 Pts, LAR eligible, uT2N1, uT3N0-1 FOXFOX/BEV x 4 FOLFOX x 2 Surgery ∙ If preop POD salvage preop RT ∙ If pT4, N2, or margin+ post RT ∙ R0: 30/30 ∙ pCR: 25% ∙ No preop RT, 2 postop RT ∙ 4 years: 0 LF, 84% DFS * Alliance N1048 – 1000 pt trial Schrag et al JCO 2014

  12. Preop CMT – Selective RT • 28 pts, Multicenter phase II • MRI: T3 or > 2mm from mesorectal fascia (? LN) • Mid rectal (> 5 cm from AV) • 4 cycles Induction CAPOX-B • None required preop CMT • 15 % pCR, all R0 • 2 pts with pN2 needed postop CMT • 50% Gr 3+ toxicity Fernandez-Martos et al, ProcASCO 2012

  13. ….Yes · Local recurrences in rectal cancer occur late · LN+ is primary cause of LF · 22% ypN+ even after preop CMT for cT3N0 · LN + is independent of distance from AV ·CT alone data are investigational and may have higher toxicity

More Related